1
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas DP Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt Activity. Merck And Co, November 20, 2008: US20080287457-A1

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


2
Kevin Rodzinak
Mark E Layton, Kevin J Rodzinak, Michael J Kelly, Philip E Sanderson: 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists. Merck And Co, December 20, 2007: US20070293515-A1

Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, ...


3
Kevin Rodzinak
Mark E Layton, Kevin J Rodzinak, Philip E Sanderson: Inhibitors of akt activity. Merck And Co, January 28, 2010: US20100022573-A1

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


4

5
Marc Feiglin: Sealing apparatus for use with microplates. Merck And Co, July 12, 2001: US20010007642-A1 (2 worldwide citation)

The present invention relates to a sealing apparatus that effectively seal microplates and can be used in conjunction with automated equipment. While the present invention is adaptable to automated instruments, it does not require sophisticated machinery to utilize the apparatus.


6
Michela Bettati, Mark Chambers, Simon Charles Goodacre, David James Hallett, Michael Geoffrey Neil, Leslie Jospeh Street: Imidazo-triazine derivatives as ligands for gaba receptors. Merck And Co, July 28, 2005: US20050165023-A1 (1 worldwide citation)

A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, and substituted on the phenyl ring by one or two further ...


7
Takahiro Itoh, Toshiaki Mase, Atsushi Akao: Method For Producing Thioether Compound. Merck And Co, May 8, 2008: US20080108823-A1 (1 worldwide citation)

Disclosed is an efficient and widely-applicable method for commercially producing a thioether compound or a thiol compound which is useful as a pharmaceutical compound or a production intermediate of it. Specifically disclosed is a method for producing a thioether compound represented by the general ...


8
Osamu Okamoto, Jean Pierre Falgueyret, Renata Marcella Oballa, Petpiboon Prasit, Robert Rydzewski: Cathepsin cysteine protease inhibitors. Merck And Co, December 11, 2003: US20030229226-A1 (1 worldwide citation)

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.


9
Byron Halevy, Matthew Paul, Donghui Cui, Stacey Lynn Polsky, A David Rodrigues, Jose Miguel Vega, Stanley Vickers: Glucoronide adduct as gaba ligand. Merck And Co, December 23, 2004: US20040259818-A1 (1 worldwide citation)

The quaternary ammonium N-glucuronide adduct of 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-yl-methoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine is cleavable by glucuronidase enzymes in the body and can thereby act as a prodrug of a therapeutic agent which is a selective ligand for ...


10
Michael W McGlynn, Mandana Asgharnejad: Sustained release drug dispersion delivery device. Merck & Co, Merck And Co, September 26, 2002: US20020136744-A1 (1 worldwide citation)

The present invention is related to a drug delivery device, that is pH insensitive, for the sustained in situ production and release of a dispersion, in an environment of use, which comprises a) a compressed core prepared from an admixture comprising i) a therapeutically effective amount of a benefi ...



Click the thumbnails below to visualize the patent trend.